Top 300 Pharmacy Drug Cards


Class: Urinary Antispasmodic

Dosage Forms. Extended-Release Tablet: 7.5 mg, 15 mg


Common FDA Label Indication, Dosing, and Titration.

1. Overactive bladder: 7.5 mg po daily, may titrate to 15 mg po daily

Off-Label Uses. None

MOA. Darifenacin is a competitive muscarinic receptor antagonist. Muscarinic receptors play an important role in several major cholinergically mediated functions, including contractions of the urinary bladder smooth muscle and stimulation of salivary secretion.

Drug Characteristics: Darifenacin


Medication Safety Issues: Darifenacin


Drug Interactions: Darifenacin


Adverse Reactions: Darifenacin


Efficacy Monitoring Parameters. Resolution of clinical signs of bladder spasticity, incontinence, urinary urgency and frequency.

Toxicity Monitoring Parameters. Severe anticholinergic effects (dry mouth, cognitive impairment, constipation, vision changes).

Key Patient Counseling Points. This drug may cause anticholinergic effects including constipation, urinary retention, blurred vision, constipation, dyspepsia, or xerostomia. Heat prostration (due to decreased sweating) can occur when used in a hot environment.

Clinical Pearls. May note decline in cognitive function, especially in elderly patients.

If you find an error or have any questions, please email us at Thank you!